Compare ThredUp Inc (TDUP) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ThredUp Inc vs BIO-TECHNE Corp — how do they compare? ThredUp Inc trades at $3.05 (market cap $415.01M), while BIO-TECHNE Corp trades at $72.26 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 27.1× ThredUp Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| TDUP | TECH | |
|---|---|---|
Market Cap | $415.01M | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.08 | $72.29 |
52-Week Low | $3.11 | $43.31 |
Enterprise Value | $413.19M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ThredUp (TDUP) trades at $3.095, down 4.18% on the day, reflecting negative market reaction to recent earnings. The stock is technically bearish with key indicators showing mixed signals. Fundamentally, the company reported Q2 2026 revenue growth of 17% to $90.8 million but missed EPS expectations and cut its full-year revenue outlook, highlighting ongoing profitability challenges.
The outlook is cautious. While analyst consensus is a 'Buy' (57% of ratings), recent news indicates significant promotional headwinds and shareholder investigations. The primary opportunity lies in the company's strong gross margin and active buyer growth, but risks include persistent net losses and execution uncertainty. The stock's trajectory hinges on achieving profitability.
TECH trades at $72.25, up 0.18% today, with a bullish technical signal and moving averages supporting an uptrend. The company reported Q4 2026 earnings of $0.52 per share, meeting estimates, while revenue beat expectations on strong research and diagnostics demand. Financials show a gross profit margin of 64.96%, but net income margin has declined to 9.05% in 2025 from 25.09% in 2023. Analyst consensus is evenly split between Buy and Hold, with a price target of $71.67.
The stock presents a mixed outlook: strong cash flow and institutional interest contrast with high valuation multiples and margin compression. Key risks include competitive pressures and execution challenges in maintaining profitability. Upside potential hinges on sustained revenue growth and margin recovery, but investors should weigh the elevated P/E of 103 against earnings stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
